Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe

Clinical Infectious Diseases

Volumn 55, Issue 12, 2012, Pages 1707-1718

  Walker, A Sarah ^a   Prendergast, Andrew J ^a,b   Mugyenyi, Peter ^c   Munderi, Paula ^d   Hakim, James ^e   Kekitiinwa, Addy ^f   Katabira, Elly ^g   Gilks, Charles F ^h   Kityo, Cissy ^c   Nahirya Ntege, Patricia ^d   Nathoo, Kusum ⁱ   Gibb, Diana M ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^f Baylor Uganda Pediatric Infectious Disease Centre   (Uganda)

^g MAKERERE UNIVERSITY   (Uganda)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIV OF ZIMBABWE MEDICAL SCHOOL   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS TENOFOVIR PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; UREA; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD CELL COUNT; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILD; CONCENTRATION (PARAMETERS); DISEASE SURVEILLANCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORTALITY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SEPTICEMIA; UGANDA; ZIMBABWE;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; RISK; UGANDA;

EID: 84870223640     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis797     Document Type: Article

References (57)

1. World Health Organization. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2011. Geneva, Switzerland: WHO, 2011. Available at: Http://whqlibdoc.who.int/publications/ 2011/9789241502986-eng.pdf. Accessed 18 December 2011.
2. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet 2006; 367:817-24.
3. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678-87.
4. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010; 24:2263-70.
5. Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One 2010; 5:e13268.
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 revision. Geneva, Switzerland: WHO, 2010.
7. Katz IT, Essien T, Marinda ET, et al. Antiretroviral refusal among newly diagnosed HIV-infected adults in Soweto, South Africa. AIDS 2011; 25:2177-81.
8. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resourcelimited settings. Curr Opin HIVAIDS 2010; 5:18-26.
9. Moore DM, Yiannoutsos CT, Musick BS, et al. Determinants of early and late mortality among HIV-infected individuals receiving homebased antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2011; 58:289-96.
10. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One 2011; 6: E21795.
11. Zachariah R, Harries K, Moses M, et al. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health 2009; 14:713-21.
12. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-60.
13. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51:615-23.
14. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 2006; 25:127-41.
15. Weigel R, Estill J, Egger M, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 2012; 26:365-73.
16. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): A randomised non-inferiority trial. Lancet 2010; 375:123-31.
17. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006. Available at: Http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf. Accessed 17 September 2012.
18. DART Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as firstline antiretroviral therapy: A randomized double-blind trial (NORA). Trop Med Int Health 2008; 13:6-16.
19. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.
20. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002; 21:2175-97.
21. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J 2009; 9:265-90.
22. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-Term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398-404.
23. Boyd K, Dunn DT, Castro H, et al. Discordance between CD4 cell count and CD4 cell percentage: Implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 2010; 24:1213-7.
24. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-Aged children and adolescents. Bull World Health Organ 2007; 85:660-7. (Pubitemid 47416716)
25. World Health Organization. WHO child growth standards: Methods and development: Length/height-for-Age, weight-for-Age, weight-forlength, weight-for-height and body mass index-for-Age. Geneva, Switzerland: WHO, 2006.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
27. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resourcelimited settings: Systematic review and meta-Analysis. PLoS One 2009; 4:e5790.
28. Mulder DW, Nunn AJ, Wagner HU, Kamali A, Kengeya-Kayondo JF. HIV-1 incidence and HIV-1-Associated mortality in a rural Ugandan population cohort. AIDS 1994; 8:87-92.
29. 3Cs4kids Cohort Collaboration. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: A metaanalysis. AIDS 2008; 22:97-105.
30. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr 2011; 56:59-63.
31. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-81.
32. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-91.
33. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
34. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low-And middle-income countries (LMIC): A systematic review and meta-Analysis. PLoS One 2012; 6:e28691.
35. Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002; 21: 54-6. (Pubitemid 34073960)
36. Abadi J, Nachman S, Kressel AB, Pirofski L. Cryptococcosis in children with AIDS. Clin Infect Dis 1999; 28:309-13.
37. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:796-800.
38. Parkes-Ratanshi R, Kamali A, Wakeham K, et al. Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV-infected Ugandan adults. In: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009. Abstract 32.
39. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; CD000171.
40. Walker AS, Ford D, Gilks CF, et al. Daily co-Trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: An observational analysis of the DART cohort. Lancet 2010; 375:1278-86.
41. World Health Organization. Guidelines on co-Trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.
42. Grinsztejn B, Veloso VG, Friedman RK, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS 2009; 23:2107-14.
43. Lumbiganon P, Kariminia A, Aurpibul L, et al. Survival of HIV-infected children: A cohort study from the Asia-Pacific region. J Acquir Immune Defic Syndr 2011; 56:365-71.
44. Liu E, Spiegelman D, Semu H, et al. Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. Journal Infect Dis 2011; 204:282-90.
45. Koethe JR, Chi BH, Megazzini KM, Heimburger DC, Stringer JS. Macronutrient supplementation for malnourished HIV-infected adults: A review of the evidence in resource-Adequate and resourceconstrained settings. Clin Infect Dis 2009; 49:787-98.
46. Nyanzi-Wakholi B, Lara AM, Munderi P, Gilks C. The charms and challenges of antiretroviral therapy in Uganda: The DART experience. AIDS Care 2012; 24:137-42.
47. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H, Manary MJ. Supplementary feeding with either ready-To-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: Randomised, investigator blinded, controlled trial. BMJ 2009; 338:b1867.
48. Paton NI, Chua YK, Earnest A, Chee CB. Randomized controlled trial of nutritional supplementation in patients with newly diagnosed tuberculosis and wasting. Am J Clin Nutr 2004; 80:460-5.
49. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298:1888-99.
50. Fenner L, Brinkhof MW, Keiser O, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 2010; 54:524-32.
51. Hoffmann CJ, Fielding KL, Johnston V, et al. Changing predictors of mortality over time from cART start: Implications for care. J Acquir Immune Defic Syndr 2011; 58:269-76.
52. Parrott FR, Mwafulirwa C, Ngwira B, et al. Combining qualitative and quantitative evidence to determine factors leading to late presentation for antiretroviral therapy in Malawi. PLoS One 2011; 6:e27917.
53. Dickson N, McAllister S, Sharples K, Paul C. Late presentation of HIV infection among adults in New Zealand: 2005-2010. HIV Med 2012; 13:182-9.
54. Zoufaly A, An der Heiden M, Marcus U, et al. Late presentation for HIV diagnosis and care in Germany. HIV Med 2012; 13:172-81.
55. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15(suppl 1):3-8.
56. Sabin CA, Smith CJ, Youle M, et al. Deaths in the era of HAART: Contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20:67-71.
57. Paton N, for the Hydroxychloroquine Trial Team. Effects of hydroxychloroquine on immune activation in ART-naive patients: A 48-week randomised, double-blind, placebo-controlled trial. In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.